Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Subvenite price, strengths & recalls

Brand of lamotrigine (generic)

Pharmacies pay $2.06 for 30 tablets of Subvenite 150 mg tablet this week, and from $0.81 to $687.43 across its 5 priced strengths and forms. The generic, lamotrigine, costs pharmacies from $0.81. It is in shortage (being discontinued). It has 13 recalls on record, none ongoing. Its official label last changed on October 21, 2026.

Being discontinuedBrand
Pharmacies pay$2.06for 30 tablets of 150 mg tablet-1.0% in 4 weeks
Fair cash price
$12.87
Strengths
5
Makers
1
Updated
Nov 11

Subvenite price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
10 mg/mL oral suspension Brand$2.86$687.43 / 240 mL+0.1%
Orange (for patients not taking carbamazepine, phenytoin, phenobarbital, primidone, or valproate) pack BrandNot priced this week
25 mg tablet Brand$0.0270$0.81 / 30 tablets+0.8%-11.8%
100 mg tablet Brand$0.0483$1.45 / 30 tablets-0.8%+5.4%
150 mg tablet Brand$0.0688$2.06 / 30 tablets-1.0%+9.3%
200 mg tablet Brand$0.0801$2.40 / 30 tablets-2.9%+1.8%

The lowest cost per tablet is 25 mg tablet at $0.0270. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Subvenite vs generic lamotrigine

Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:

StrengthBrandGenericBrand costs
25 mg tablet$0.81$0.81-
100 mg tablet$1.45$1.45-
150 mg tablet$2.06$2.06-
200 mg tablet$2.40$2.40-
GenericLamotrigine prices

Supply status: shortages & recalls

In shortage6 products are short or being discontinued
No ongoing recalls13 recalls on record

Shortages

  • Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11)Par Health, Inc. · Being discontinued Apr 29, 2026 · Updated Apr 29, 2026Discontinuation of the manufacture of the drug
  • Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11)Par Health, Inc. · Being discontinued Apr 29, 2026 · Updated Apr 29, 2026Discontinuation of the manufacture of the drug
  • Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11)Par Health, Inc. · Being discontinued Apr 29, 2026 · Updated Apr 29, 2026Discontinuation of the manufacture of the drug
  • Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11)Par Health, Inc. · Being discontinued Apr 29, 2026 · Updated Apr 29, 2026Discontinuation of the manufacture of the drug
  • Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11)Par Health, Inc. · Being discontinued Apr 29, 2026 · Updated Apr 29, 2026Discontinuation of the manufacture of the drug
  • Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11)Par Health, Inc. · Being discontinued Apr 29, 2026 · Updated Apr 29, 2026Discontinuation of the manufacture of the drug

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

Showing the 6 most relevant of 13 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for subvenite? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedOctober 21, 2026
Version4 of 4
EffectiveAug 26, 2026
Read the label

These highlights do not include all the information needed to use SUBVENITE® safely and effectively. See full prescribing information for SUBVENITE®.SUBVENITE (lamotrigine) oral suspensionInitial U.S. Approval: 1994

This drug has a boxed warning

WARNING: SERIOUS SKIN RASHES

SUBVENITE can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving lamotrigine. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking lamotrigine as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.

In addition to age, factors that may increase the risk of occurrence or the severity of rash caused by lamotrigine include (1) coadministration of lamotrigine with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of SUBVENITE, (3) exceeding the recommended dose escalation for SUBVENITE, or (4) the presence of the HLA-B*1502 allele. However, cases have occurred in the absence of these factors.

Nearly all cases of life-threatening rashes caused by lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.

Although benign rashes are also caused by lamotrigine, it is not possible to predict reliably which rashes will prove to be serious or life threatening. Accordingly, SUBVENITE should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug related. Discontinuation of treatment may not prevent a rash from becoming life threatening or permanently disabling or disfiguring [see Warnings and Precautions (5.1)].

WARNING: SERIOUS SKIN RASHES

See full prescribing information for complete boxed warning.

Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine, the active ingredient in SUBVENITE. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:

coadministration with valproate.

exceeding recommended initial dose of SUBVENITE.

exceeding recommended dose escalation for SUBVENITE.

presence of the HLA-B*1502 allele. (5.1)

Benign rashes are also caused by lamotrigine, the active ingredient in SUBVENITE; however, it is not possible to predict which rashes will prove to be serious or life threatening. SUBVENITE should be discontinued at the first sign of rash, unless the rash is clearly not drug related. (5.1)

Recent major changes (as listed on the label)

Boxed Warning | 08/2026 |

Warnings and Precautions (5.1) | 08/2026 |

Warnings and Precautions (5.4) | 08/2026 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA218879 · Owp Pharms
First approved
September 16, 2025 (1 year ago)
Latest approved change
July 17, 2026
Approved label
PDF, Jul 21, 2026
Generic makers
27 approved generic applications on the market
Last patent listed
May 29, 2040

Subvenite questions

How much does subvenite cost without insurance?

Pharmacies pay about $2.06 for 30 tablets of subvenite 150 mg tablet ($0.0688 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $12.87. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Subvenite?

Yes: lamotrigine. Pharmacies pay from $0.81 for it. Compare lamotrigine prices.

Is subvenite in shortage?

Yes. 6 products are listed as in shortage or being discontinued (being discontinued). See which ones.

Has subvenite been recalled?

13 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the subvenite label last change?

The official label was last updated on October 21, 2026 (version 4). See what changed.

Talk about subvenite

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.